Report: Injectable antibodies top growth chart

10/11/2007 | NYTimes.com

Sales of injectable monoclonal antibodies will grow 14% annually from 2006 to 2012, preserving their status as the fastest-growing class of drugs during the next five years, market analyst Datamonitor says in its latest report. Antibody-based drugs already are popular for the treatment of cancer and rheumatoid arthritis and currently generate $20 billion in global revenue.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC